FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2789826025> ?p ?o ?g. }

• W2789826025 endingPage "1055" @default.
• W2789826025 startingPage "1043" @default.
• W2789826025 abstract "Abstract In the Asia‐Pacific region, treatment options are limited for patients with relapsed/refractory chronic lymphocytic leukemia ( CLL )/small lymphocytic lymphoma ( SLL ). Rituximab is widely used in this setting when purine analog‐based therapies are not appropriate. We evaluated the efficacy and safety of ibrutinib compared with rituximab in a randomized, open‐label phase 3 study in predominantly Asian patients with relapsed/refractory CLL / SLL . Patients ( N = 160) were randomly assigned 2:1 to receive 420 mg ibrutinib ( n = 106) until disease progression ( PD ) or unacceptable toxicity or up to six cycles of rituximab ( n = 54). The primary endpoint was investigator‐assessed progression‐free survival ( PFS ); key secondary endpoints were overall response rate ( ORR ), overall survival ( OS ), and safety. Rituximab‐treated patients could crossover to receive ibrutinib after confirmed PD . At data cutoff, median treatment duration was 16.4 months for ibrutinib and 4.6 months for rituximab. Ibrutinib significantly improved PFS (hazard ratio [ HR ] = 0.180, 95% confidence interval [ CI ]: 0.105–0.308). ORR was significantly higher ( P < 0.0001) with ibrutinib (53.8%) than with rituximab (7.4%). At a median follow‐up of 17.8 months, ibrutinib improved OS compared with rituximab ( HR = 0.446; 95% CI : 0.221–0.900; P = 0.0206). Overall incidence of adverse events ( AE s) was similar between treatments and was not exposure‐adjusted. With ibrutinib, most common AE s were diarrhea and platelet count decreased; with rituximab, most common AE s were neutrophil count decreased and platelet count decreased. Grade ≥3 AE s were reported in 82.7% of ibrutinib‐treated patients and 59.6% of rituximab‐treated patients. Ibrutinib improved PFS , ORR , and OS compared with rituximab and displayed a manageable safety profile in Asian patients with relapsed/refractory CLL / SLL ." @default.
• W2789826025 created "2018-03-29" @default.
• W2789826025 creator A5000239300 @default.
• W2789826025 creator A5017804632 @default.
• W2789826025 creator A5022597400 @default.
• W2789826025 creator A5024190612 @default.
• W2789826025 creator A5027220663 @default.
• W2789826025 creator A5034579434 @default.
• W2789826025 creator A5040795581 @default.
• W2789826025 creator A5045814990 @default.
• W2789826025 creator A5048988662 @default.
• W2789826025 creator A5055494772 @default.
• W2789826025 creator A5055577592 @default.
• W2789826025 creator A5057401157 @default.
• W2789826025 creator A5060513862 @default.
• W2789826025 creator A5071319862 @default.
• W2789826025 creator A5071443000 @default.
• W2789826025 creator A5074069807 @default.
• W2789826025 creator A5077970092 @default.
• W2789826025 creator A5081083731 @default.
• W2789826025 creator A5081203691 @default.
• W2789826025 creator A5086118866 @default.
• W2789826025 creator A5086151596 @default.
• W2789826025 creator A5090610771 @default.
• W2789826025 creator A5091815974 @default.
• W2789826025 date "2018-03-13" @default.
• W2789826025 modified "2023-10-16" @default.
• W2789826025 title "Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study" @default.
• W2789826025 cites W1685882185 @default.
• W2789826025 cites W1804336422 @default.
• W2789826025 cites W1975590576 @default.
• W2789826025 cites W1978454290 @default.
• W2789826025 cites W1982589145 @default.
• W2789826025 cites W1986924929 @default.
• W2789826025 cites W1998185169 @default.
• W2789826025 cites W2025337992 @default.
• W2789826025 cites W2026663422 @default.
• W2789826025 cites W2058220692 @default.
• W2789826025 cites W2059319347 @default.
• W2789826025 cites W2066388140 @default.
• W2789826025 cites W2066564017 @default.
• W2789826025 cites W2071549499 @default.
• W2789826025 cites W2072620152 @default.
• W2789826025 cites W2074072603 @default.
• W2789826025 cites W2077532696 @default.
• W2789826025 cites W2094252783 @default.
• W2789826025 cites W2108206643 @default.
• W2789826025 cites W2129041705 @default.
• W2789826025 cites W2133205391 @default.
• W2789826025 cites W2136475569 @default.
• W2789826025 cites W2140606816 @default.
• W2789826025 cites W2141880470 @default.
• W2789826025 cites W2142099365 @default.
• W2789826025 cites W2144617723 @default.
• W2789826025 cites W2146029333 @default.
• W2789826025 cites W2164056717 @default.
• W2789826025 cites W2212600795 @default.
• W2789826025 cites W2229634057 @default.
• W2789826025 cites W2233614027 @default.
• W2789826025 cites W2292980097 @default.
• W2789826025 cites W2327890341 @default.
• W2789826025 cites W2550091596 @default.
• W2789826025 cites W2550935748 @default.
• W2789826025 cites W2592506294 @default.
• W2789826025 cites W2626951690 @default.
• W2789826025 cites W3049379535 @default.
• W2789826025 cites W4251009301 @default.
• W2789826025 doi "https://doi.org/10.1002/cam4.1337" @default.
• W2789826025 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5911578" @default.
• W2789826025 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29533000" @default.
• W2789826025 hasPublicationYear "2018" @default.
• W2789826025 type Work @default.
• W2789826025 sameAs 2789826025 @default.
• W2789826025 citedByCount "30" @default.
• W2789826025 countsByYear W27898260252018 @default.
• W2789826025 countsByYear W27898260252019 @default.
• W2789826025 countsByYear W27898260252020 @default.
• W2789826025 countsByYear W27898260252021 @default.
• W2789826025 countsByYear W27898260252022 @default.
• W2789826025 countsByYear W27898260252023 @default.
• W2789826025 crossrefType "journal-article" @default.
• W2789826025 hasAuthorship W2789826025A5000239300 @default.
• W2789826025 hasAuthorship W2789826025A5017804632 @default.
• W2789826025 hasAuthorship W2789826025A5022597400 @default.
• W2789826025 hasAuthorship W2789826025A5024190612 @default.
• W2789826025 hasAuthorship W2789826025A5027220663 @default.
• W2789826025 hasAuthorship W2789826025A5034579434 @default.
• W2789826025 hasAuthorship W2789826025A5040795581 @default.
• W2789826025 hasAuthorship W2789826025A5045814990 @default.
• W2789826025 hasAuthorship W2789826025A5048988662 @default.
• W2789826025 hasAuthorship W2789826025A5055494772 @default.
• W2789826025 hasAuthorship W2789826025A5055577592 @default.
• W2789826025 hasAuthorship W2789826025A5057401157 @default.
• W2789826025 hasAuthorship W2789826025A5060513862 @default.
• W2789826025 hasAuthorship W2789826025A5071319862 @default.
• W2789826025 hasAuthorship W2789826025A5071443000 @default.
• W2789826025 hasAuthorship W2789826025A5074069807 @default.
• W2789826025 hasAuthorship W2789826025A5077970092 @default.

• next